how safe is crypto currency Block

Market News: Argentine President Milei met with Rio Tinto CEO Meloni in Rome.Market News: Trump's assistant asked Trump if it was possible to abolish the Federal Deposit Insurance Corporation (FDIC).Kexing launched the world's first phase III clinical study of bivalent inactivated enterovirus vaccine. On December 13th, the first volunteer was enrolled in the phase III clinical study of bivalent inactivated enterovirus vaccine developed by Beijing Kexing Biological Products Co., Ltd., a subsidiary of Kexing Holding Biotechnology Co., Ltd. (hereinafter referred to as "Kexing"). The vaccine is used to prevent hand, foot and mouth disease caused by enterovirus 71 (EV71) and coxsackie virus 16 (CA16). A multicenter, randomized, double-blind, controlled study design was adopted in this phase III clinical study to evaluate the protective efficacy, safety and immunogenicity of the vaccine in children aged 6-71 months.

Bei Ya raised the Amazon target price from $220.00 to $260.00.Weilai announced that the number of power exchanges had exceeded 60 million times. Weilai issued a document saying that as of 21:06:08 on December 13th, 2024, Weilai had changed power more than 60 million times! Thank you for your support and trust in Weilai.Senior EU officials: The foreign ministers of 27 EU countries will approve the 15th round of sanctions against Russia and new sanctions "against hybrid operations" on December 16th.

Kangxinuo Bio: Dong Xiaoman was appointed as the new general partner of Shanghai Qianxizhi, and Kangxinuo Bio (06185) issued an announcement. On December 13, 2024, Dr. Zhu informed the board of directors that in view of the need for sufficient time to manage the employee stock ownership platform, all the partners of the employee stock ownership platform unanimously decided to appoint Well Lee as the new general partner of Shanghai Qianxiyi and Shanghai Qianxirui respectively, and Dong Xiaoman as the new general partner of Shanghai Qianxizhi. Therefore, Dr. Zhu is no longer the general partner of the employee stock ownership platform and no longer has the right to exercise the voting rights of the shares held by the employee stock ownership platform.Kang Enbei: Amikacin Sulfate Injection is planned to win the bid for the tenth batch of national centralized drug purchase. On December 12th, Kang Enbei and its wholly-owned subsidiary Jinhua Kang Enbei participated in the bidding for the tenth batch of national centralized drug purchase organized by the National Joint Procurement Office for Centralized Drug Purchase and Use. After the bid opening and bid evaluation by the Joint Procurement Office, the company's product Amikacin Sulfate Injection plans to win the bid for this centralized procurement, and the supply provinces have been selected according to the market potential of each province. The successful results will be officially released after being publicized by the Joint Procurement Office. Amikacin sulfate injection is suitable for the treatment of serious infections caused by Pseudomonas aeruginosa, other Pseudomonas, Escherichia coli and other sensitive gram-negative bacilli and Staphylococcus (methicillin-sensitive strains). Compared with the original price, the price of the product to be selected this time has dropped to a certain extent.Huawang Technology: Zhang Yancheng, the director, plans to reduce the company's shares by no more than 0.3443%. Huawang Technology announced that Zhang Yancheng, the company's director and senior manager, plans to reduce the company's shares by no more than 1.6 million shares through centralized bidding on the Shanghai Stock Exchange within three months after the announcement date, accounting for 0.3443% of the company's total share capital. The reduction price will be determined according to the market price. Zhang Yancheng currently holds 6,671,700 shares of the company, accounting for 1.4357% of the company's total share capital.